Business Valuation Zone

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

companies intercept-pharmaceuticals-inc

Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments

Benzinga

MAY 5, 2022

as well as the transition to Advanz of the international commercial and medical infrastructure of Intercept. Additionally, Intercept will receive royalties on any future ex-U.S. Intercept to discuss further details during Q1 2022 earnings call on Friday, May 6 th at 8:30 a.m. net sales of obeticholic acid in NASH.

Marketability

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

Benzinga

JANUARY 23, 2024

NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trial Program developed by Florida Biotechnologies, Inc. a gene therapy company focusing on the treatment of mitochondrial diseases. & and SARASOTA, Fla., and SARASOTA, Fla.,

Finance

Finance Marketability

Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

Stay Connected